js014
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2022 (NCT05296772)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Alpha-taxilinAGONIST
TXLNA agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06882876 | Phase 1 | Jul 10, 2025 | Central South University, Shanghai Junshi Bioscience Co.,Ltd. |
| NCT05296772 | Phase 1 | Feb 28, 2022 | Anwita Biosciences, Shanghai Junshi Bioscience Co.,Ltd., Taipei Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 2 | 0 | 1 | 2022 |
| Anwita Biosciences | For profit | 1 | 1 | 1 | 2022 |
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Taipei Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1